MwanzoSGIOY • OTCMKTS
Shionogi 4 ADR Representing Ord Shs
$ 11.12
Baada ya Saa za Kazi:
$ 11.12
(0.00%)0.00
Imefungwa: 27 Sep, 16:13:27 GMT -4 · USD · OTCMKTS · Kanusho
Nembo ya GLeafInaongoza katika utunzaji wa mazingiraHisa zinazouzwa MarekaniMakao yake makuu ni JP
Bei iliyotangulia
$ 11.24
Bei za siku
$ 10.51 - $ 11.23
Bei za mwaka
$ 9.33 - $ 13.67
Thamani ya kampuni katika soko
1.90T JPY
Wastani wa hisa zilizouzwa
elfu 42.60
Alama ya CDP ya Tabia Nchi
A
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(JPY)Jun 2024Mabadiliko Tangu Mwaka Uliopita
Mapato
97.59B-10.73%
Matumizi ya uendeshaji wa biashara
55.03B10.94%
Mapato halisi
30.64B-28.02%
Kiwango cha faida halisi
31.39-19.39%
Mapato kwa kila hisa
EBITDA
33.03B-35.20%
Asilimia ya kodi ya mapato
17.02%
Jumla ya mali
Jumla ya dhima
(JPY)Jun 2024Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
281.96B-2.46%
Jumla ya mali
1.45T6.23%
Jumla ya dhima
157.74B-8.07%
Jumla ya hisa
1.29T
hisa zilizosalia
283.49M
Uwiano wa bei na thamani
0.00
Faida inayotokana na mali
4.90%
Faida inayotokana mtaji
5.48%
Mabadiliko halisi ya pesa taslimu
(JPY)Jun 2024Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
30.64B-28.02%
Pesa kutokana na shughuli
33.50B6.74%
Pesa kutokana na uwekezaji
-90.85B-161.40%
Pesa kutokana na ufadhili
-24.83B-7.63%
Mabadiliko halisi ya pesa taslimu
-76.13B-277.88%
Mtiririko huru wa pesa
-81.81B-634.02%
Kuhusu
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
17 Mac 1878
Wafanyakazi
4,959
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu